<DOC>
	<DOCNO>NCT00004905</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Clinical trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient chronic myelogenous leukemia acute leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Chronic Myelogenous Leukemia Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity induction transplant regimens patient chronic myelogenous leukemia high-risk acute leukemia . II . Determine efficacy collect peripheral blood stem cell ( PBSC ) early hematopoietic recovery intensive chemotherapy mean vivo enrichment cytogenetically normal progenitor cell patient population . III . Correlate cytogenetic molecular response peripheral blood bone marrow clinical response , time progression , survival patient several timepoints myelosuppressive myeloablative therapy . OUTLINE : This multicenter study . Patients stratify accord disease ( chronic myelogenous leukemia v acute lymphoblastic leukemia v acute myelogenous leukemia ) . Patients receive cytarabine IV 4 hour , etoposide IV 1.5-2 hour , idarubicin IV 5-10 minute day 1 , 3 , 5 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) daily begin day 2 continue blood count recover . Chronic myelogenous leukemia : On day 14 follow chemotherapy , bone marrow biopsy show less 20 % cellularity peripheral blood sample contain great 50 % cytogenetically normal cell , patient receive second induction course follow apheresis . Patients less 50 % cytogenetically normal cell also consider second induction course . Patients response progressive disease remove study . Acute leukemia : On day 14 follow chemotherapy , bone marrow biopsy show less 20 % cellularity peripheral blood sample show 100 % cytogenetically normal cell , patient receive second induction course follow apheresis . Patients high risk disease first remission time study entry undergo apheresis recovery first course induction therapy second course may omit . Patients receive second induction course follow G-CSF first induction course . Once blood count recover , patient undergo harvest peripheral blood stem cell ( PBSC ) . Patients also undergo bone marrow stem cell collection case failure PBSC transplantation ( PBSCT ) . Patients receive follow condition regimen : total body irradiation twice day day -8 -5 ; etoposide IV 4 hour day -4 ; cyclophosphamide IV 2 hour day -2 . PBSCT conduct day 0 . G-CSF SC administer begin day 1 continue blood count recover . Patients receive maintenance therapy interferon alfa SC 3 time week 12 month . Patients follow weekly 3 month monthly death . PROJECTED ACCRUAL : Approximately 15 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow hematologic condition : Chronic phase advance chronic myelogenous leukemia Acute lymphoblastic leukemia : relapsed second remission later first remission unfavorable prognostic feature Acute myelogenous leukemia : second remission later first remission highrisk feature Detectable clonal cytogenetic molecular abnormality time diagnosis Not eligible allogenic bone marrow transplant PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT/SGPT le 2 time ULN Renal : Creatinine clearance great 60 mL/min Cardiovascular : Ejection fraction great 45 % Pulmonary : DLCO great 60 % FEV1 great 60 % Other : No serious underlie medical condition would preclude study Not pregnant nursing No cerebellar dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Prior chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
</DOC>